During the September quarter , Vertex’s revenue from its drug Trikafta amounted to $2.27 billion. While this figure fell slightly short of the expectations of RBC Capital Markets analyst Brian Abrahams, who had predicted $2.33 billion, it aligned with the estimate provided by Piper Sandler analyst Christopher Raymond.
Sales from other cystic fibrosis drugs brought in $209.2 million, which definitively missed the forecasts that had predicted figures ranging from $228 million to $229 million, as reported by analysts.
In a bearish turn of events, Vertex unexpectedly halted the development of a potential liver disease treatment due to adverse effects observed in early-stage testing, which led to the development of rashes in some patients. Additionally, the company stated that it needs to conduct further laboratory and animal testing for a gene-editing treatment intended for Duchenne muscular dystrophy before initiating human trials. the September quarter
RBC’s Abrahams characterized the quarter as reasonably solid, acknowledging that even a slight miss in revenue can have an outsized impact on the stock’s performance. However, he emphasized that the primary focus remains on Vertex’s late-stage pipeline programs, with upcoming readouts that appear to be on track.
Earnings beat projections for $3.65 a share, according to FactSet. Sales were mixed, however, topping the FactSet-polled analysts’ consensus view for $2.33 billion. Abrahams, on the other hand, expected about $2.5 billion, while Piper Sandler’s Raymond had estimates at $2.5 billion to $2.51 billion.